Research

泰然健康网
2025-08-28 03:17

Our Research

At GHDDI, we focus on translational research – from the bench to the bedside. Our scientists conduct great science and develop new technology to accelerate drug discovery for diseases that impact global population, such as COVID-19, tuberculosis, malaria etc. With diverse pipelines constructed, GHDDI have already achieved great number of breakthroughs.

RESEARCH PLATFORMS

GHDDI has successfully established an industry-leading standardized matrix system that acts as a cornerstone for the development of new small molecule drugs, with a sharp focus on multiple disease areas in the realm of biology. This state-of-the-art system is powered by medicinal chemistry, drug metabolism and pharmacokinetics (DMPK), animal laboratory, protein science and structural biology, high-throughput screening, and data science. These cutting-edge platforms play a pivotal role in drug discovery, offering unmatched precision and efficiency.

Data Science KongMing Platform

The Data Science KongMing platform is dedicated to integrating cheminformatics, bioinformatics, pharmaceutical, and medical data. Utilizing physical modeling, data-driven algorithms (statistical analysis, machine learning, deep learning), foundational large-scale models, and expert knowledge through self-developed systems and tools, it addresses real-world challenges in the drug discovery process. The platform explores technological innovations, builds fundamental technologies, and empowers more efficient drug R&D. Additionally, it manages 62 local high-performance computing clusters and over one billion biochemical and pharmaceutical data entries.

HTS

Equipped with the cutting-edge HighRes fully automated high-throughput screening system instrumentation, HTS supports multiple types of screening methods based on biological targets and cellular phenotypes. With a screening data capacity of millions of compounds (samples)/year, the platform can save time and cost. The platform has established multiple types of compound libraries, including known activity libraries, structural diversity libraries, natural product libraries, and true pair-specific disease/target libraries, with a total of over 450,000 compounds. In addition, the platform has the ReFRAME compound library, with over 12,000 clinically safe compounds.

http://hts.ghddi.org/